Metabolic syndrome and cholangiocarcinoma: large numbers, small risks, but big implications

Cholangiocarcinoma (CCA) remains a lethal malignancy with rising incidence in several regions (1). CCA is undergoing an etiologic transition where global control of chronic hepatitis B and C improves, the metabolic liver disease including its systemic correlates are poised to account for a growing fraction of new cases (2,3). Against this background, Chen and colleagues report a landmark population-based cohort analysis linking metabolic syndrome with intrahepatic (iCCA) and extrahepatic cholangiocarcinoma (eCCA) in more than 4.9 million adults, with national cancer and death registry linkage, and up to a decade of follow-up (35.9 million person-years) (4). The scale, granularity, and clinical framing of this study deserve attention from clinicians, epidemiologists, and policy-makers alike.

Key findings are consistent and clinically relevant. First, sheer size: 4.9 million individuals, among whom 6,117 developed CCA (4,625 iCCA; 1,492 eCCA), yielding robust precision. Second, iCCA and eCCA are analyzed separately, avoiding the common pitfall of lumping heterogeneous entities under “liver/biliary” cancers (5,6). Third, the East Asian context, with relatively high iCCA incidence, enhances both statistical power and external relevance for regions with similar risk profiles (1). Finally, the authors move beyond relative hazards to estimate cumulative risks, a communicable metric for clinicians and patients. Even though relative hazards are meaningfully elevated, the absolute probabilities of developing CCA over the study period remains small; 0.22% in participants with metabolic syndrome versus 0.13% without (iCCA: 0.17% vs. 0.10%; eCCA: 0.05% vs. 0.03%). For any individual patient, the absolute probability of developing CCA remains low. Presenting both relative and absolute risks avoids over-medicalization. Clinicians should therefore pair advice on cardiometabolic risk reduction with a realistic perspective: metabolic syndrome increases risk, but most patients will never develop CCA.

The main finding is consistent and intuitive: metabolic syndrome is associated with a ~20% higher adjusted subdistribution hazard for CCA overall [adjusted hazard ratio (HR): 1.20, 95% confidence interval (CI): 1.14–1.27], with similar elevations for iCCA (adjusted HR: 1.18, 95% CI: 1.11–1.25) and eCCA (adjusted HR: 1.28, 95% CI: 1.16–1.42) after adjustment for age, sex, smoking, alcohol, exercise, gallstones, biliary tract disease, and elevated liver enzymes (4). Risk rises in a dose-response fashion with the number of metabolic syndrome components (P-trend <0.0001) (4). Importantly, these associations persist in analyses accounting for chronic hepatitis B virus (HBV)/hepatitis C virus (HCV), reinforcing the notion that metabolic drivers will increasingly shape CCA epidemiology as viral hepatitis recedes (4).

Two aspects merit further discussion:

• Hepatic steatosis index (HSI). One-third of the cohort had HSI ≥36, yet no strong gradient with CCA emerged. This may reflect measurement error (HSI is indirectly constructed and partly body mass index-driven), threshold effects, or confounding by inflammation/fibrosis not captured by aminotransferases. Future studies using imaging (ultrasound, magnetic resonance imaging) and elastography should clarify whether hepatic steatosis or fibrotic remodeling is the proximate carcinogenic driver, and whether risks differ between iCCA and eCCA.
• Physical activity. Exercise was included as a covariate (none; <2.5 h/week; ≥2.5 h/week) with most participants reporting either no regular activity or <2.5 h/week at baseline. While the current analysis adjusts for activity, several clinically relevant questions remain open: Is there effect modification by exercise dose? Does meeting or exceeding recommended thresholds attenuate CCA risk within metabolic syndrome strata?

The investigators employed standardized metabolic syndrome criteria [National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III with Asian waist cutoffs], national registry linkage, cause-specific hazard modeling with competing risk considerations, stratification by CCA subsite, and cumulative incidence presentation. The East Asian context, with high gallstone prevalence and non-negligible viral hepatitis burden (7), provides a rigorous stress test for whether metabolic syndrome matters after accounting for established risks. For clinicians, the practical take-home message is straightforward: in patients with metabolic syndrome, particularly with multiple components, maintain a heightened index of suspicion for biliary tract symptoms, and work on metabolic risk modification. Screening for CCA is not warranted on the basis of metabolic syndrome alone. Generalizability to Western populations may be limited given differing viral hepatitis prevalence, gallstone patterns, and obesity phenotypes, although the metabolic drivers are globally convergent.

For public health, the message is broader. Even modest relative risks (20–30%) translate into a meaningful population burden given the high prevalence of metabolic syndrome. As hepatitis elimination advances, the relative share of CCA linked to adiposity, dysglycemia, dyslipidemia, and hypertension will grow, echoing the shift already seen in hepatocellular carcinoma. Prevention policies targeting weight management, diabetes prevention, lipid and blood pressure control, alcohol moderation, and physical activity are therefore likely to yield dividends for biliary tract cancers as well.

As with other observational study, selection and measurement features shape inference. Participation in health-check cohorts is voluntary; enrollees may differ from the general population on unmeasured health behaviors, health literacy, and access to care. While such selection need not bias internal comparisons if exposure-outcome relations are preserved, it can limit generalizability. Second, metabolic syndrome was assessed at baseline; duration and dynamics of metabolic exposure are unknown. Does five years of metabolic syndrome confer the same CCA risk as twenty? Are risk elevations reversible with sustained metabolic improvement? Clarifying dose-time relationships should be a priority, ideally with repeated measures and causal modeling.

Third, even with careful covariate adjustment, including smoking, alcohol, gallstones, biliary tract disease, and transaminases, residual confounding is possible. Granular viral data (HBV DNA, HCV RNA), imaging-confirmed steatosis/fibrosis, and medication exposures (e.g., statins, metformin, GLP-1 receptor agonists, SGLT2 inhibitors) could refine estimates and reveal intervention sensitive risks, as several of these agents have been associated with reduced hepatobiliary cancer risk in meta-analyses. Emerging meta-analyses suggest that statins and certain antidiabetic agents may attenuate CCA risk, underscoring the potential for metabolic-targeted prevention. Fourth, while the authors disaggregate iCCA and eCCA, etiologic heterogeneity within those categories (perihilar vs. distal eCCA; small-duct vs. large-duct iCCA) and molecular subtypes were beyond scope but are increasingly relevant for prevention and early detection strategies.

Finally, the absolute risks were lower over the ~7.6 years of follow-up. This is important for communication: individualized CCA screening is not justified in metabolic syndrome, unlike in primary sclerosing cholangitis where baseline risk is far higher.

Chen et al. provide a rigorous epidemiologic foundation. Next steps include:

• Causal mediation and trajectories. Partition how much of the metabolic syndrome –CCA relationship is mediated by hepatic steatosis, steatohepatitis, fibrosis, gallstones, or systemic inflammation.
• Refined phenotyping. Replace proxy indices with imaging-defined fat and stiffness, and integrate genomics, bile acid biology, and microbiome signatures to map pathway-specific risks for iCCA vs. eCCA.
• Actionable prevention. Evaluate whether intensive metabolic control (dietary programs, structured physical activity, weight-loss pharmacotherapy, bariatric surgery in selected patients) lowers incident CCA in high-risk populations.
• Absolute-risk tools. Develop calculators combining age, sex, metabolic syndrome components, gallstone history, and liver metrics to identify subgroups with sufficiently high absolute risk to merit surveillance trials, especially in high incidence regions.
• Mechanistic integration. Elucidate how insulin resistance, bile-acid signaling, chronic inflammation, and fibrotic remodeling intersect to promote biliary carcinogenesis, and identify intervention points within these pathways.

Chen et al. provide high-quality evidence from a uniquely large, well-phenotyped cohort that metabolic syndrome increases the risk of both iCCA and eCCA in a dose-responsive, virology-independent fashion (4). The effect sizes are modest, absolute risks remain low, and the clinical message is calibrated: do not screen for CCA on the basis of metabolic syndrome alone, but do treat metabolic syndrome aggressively for broad health gains. As viral hepatitis recedes, the contribution of metabolic factors to biliary tract cancer will grow. The study sets a clear agenda for mechanistic, longitudinal, and interventional research and provides clinicians with the nuance needed for patient counseling today.

Acknowledgments

None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, HepatoBiliary Surgery and Nutrition. The article has undergone external peer review.

Peer Review File: Available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-2025-744/prf

Funding: None.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-2025-744/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Qurashi M, Vithayathil M, Khan SA. Epidemiology of cholangiocarcinoma. Eur J Surg Oncol 2025;51:107064. [Crossref] [PubMed]
2. Lee TY, Hsu YC, Yu SH, et al. Effect of Nucleos(t)ide Analogue Therapy on Risk of Intrahepatic Cholangiocarcinoma in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol 2018;16:947-954.e4. [Crossref] [PubMed]
3. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020;17:557-88. [Crossref] [PubMed]
4. Chen TI, Chen MH, Yin SC, et al. Associations between metabolic syndrome and cholangiocarcinoma risk: A large-scale population-based cohort study. Hepatology 2026;83:261-75. [Crossref] [PubMed]
5. Parsi MA. Obesity and cholangiocarcinoma. World J Gastroenterol 2013;19:457-62. [Crossref] [PubMed]
6. Yang W, Sun Y. Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview. Onco Targets Ther 2021;14:1341-66. [Crossref] [PubMed]
7. Younossi ZM, Wong G, Anstee QM, et al. The Global Burden of Liver Disease. Clin Gastroenterol Hepatol 2023;21:1978-91. [Crossref] [PubMed]